Accueil   Diary - News   All news

News

Poxel
May 23th, 2017POXEL is biopharmaceutical company focused on the development of innovative drugs to treat metabolic diseases, including type 2 diabetes. It has just presented positive top line Phase 2bdata results for Imeglimin for the treatment of type 2 diabetes in Japan.
Microlight 3D is the winner of the Medi’Nov 2017 Innovation Trophy
April 20th, 2017Le salon a récompensé la technologie d’impression 3D à résolution submicronique de l’entreprise Microlight3D, issue de l’Université Grenoble Alpes.
Synthelis launches a new High Throughput Multigene Expression service
March 21th, 2017Synthelis, a French biotech company, specialized in cell-free production, purification and characterization of difficult-to-express proteins (ion channels, transporters, GPCRs,...
Edelris Announces Research Collaboration Agreement with Pfizer Inc.
February 23th, 2017Edelris is a contract research company, providing services to Life Sciences customers and partners (pharmas, biotechs and academics), committed to...
Nouveal e-health
January 30th, 2017Nouveal e-health is a software editor in connected health and is the editor of e-fitback, the solution for patient...
SYNAPCELL
Décember 20th, 2016The University of Utah has awarded a subcontract to SynapCell as part of the NIH/NINDS Epilepsy Therapy Screening Program (ETSP).


Novasep and Japanese agent AR Brown extend partnership
November 18th, 2016Stronger local representation in growing Japanese biopharma market will improve Novasep’s cap a city to equip and service Japanese clients
PX’Therapeutics and RELIEF THERAPEUTICS announce a strategic collaboration agreement
October 5th, 2016This strategic collaboration agreement concerns the production of atexakin alfa, a low-dose formulation of the recombinant human protein interleukin 6.


Alma Bio Therapeutics
September 29th, 2016Alma is a healthcare company working to help people who suffer from autoimmune diseases, such as Crohn's Disease and Rheumatoid Arthritis.Alma is making preparations for the therapy to be tested in people suffering from Crohn's Disease. A crowfunding campaign is in progress...
Valneva Announces Successful Generation of a Highly-purified Zika Vaccine Candidate
July 11th, 2016Valneva SE (“Valneva” or “the Company”), a leading pure play vaccine company, today announced that it successfully generated a...
SUBLIMED raises more than 700 000 €
June 24th, 2016SUBLIMED raises more than 700 000 € to industrialize its medical device of the pain treatment.
Focus on Alizée Pharma
May 26th, 2016Alizé Pharma II, a company of the Alizé Pharma Group, acquired by Jazz Pharmaceuticals.
Keranova raises €4m
April 12th, 2016Keranova raises €4m ($4.55 m) in series A funding. Investment will finance development of prototypes for new ophthalmic surgery equipment and launch of a preclinical study.
DIABELOOP
February 29th, 2016DIABELOOP
ENYO Pharma announces closing of a €22 million funding round
February 10th, 2016ENYO Pharma announces closing of a €22 million funding round
Innate Pharma in-licenses Orega Biotech's first-in-class anti-CD39 checkpoint inhibitor program
January 11th, 2016Innate Pharma in-licenses Orega Biotech's first-in-class anti-CD39 checkpoint inhibitor program
AAA Reports 37% growth in sales for the 3th quarter of 2015
Décember 14th, 2015With the announcement of positive Phase 3 results from the NETTER-1 trial, and the subsequent completion of a successful initial public offering in November, AAA believes to be well positioned to advance the development of our lead drug candidate Lutathera in patients with advanced midgut neuroendocrine tumors.
ElsaLys Biotech raising 2,7 M€
November 3th, 2015ElsaLys Biotech lève 2,7 millions d'euros
EVEON sign a new industrial partnership
October 9th, 2015EVEON, designer and manufacturer of medical devices for the preparation and/or administration of medicines, announces the signing of a...
Pragma Therapeutics
July 29th, 2015Pragma Therapeutics has the French status of “Young innovative Company”, and joined the incubator Pulsalys based in Lyon last...
PDC*line Pharma receives ATMP classification
June 23th, 2015PDC*line Pharma receives Advanced-Therapy Medicinal Product (ATMP)classification from the European Medicines Agency (EMA) for its new class oftherapeutic cancer...
Focus on Kallistem
April 27th, 2015Kallistem is a  Lyonbiopole member company which started its 1st fundraiser via Wiseed, a crowdfunding platform for the financing...
Focus on Alizé Pharma
March 26th, 2015Alizé Pharma, a company member of Lyonbiopole,announces that it has raised €1.8 million (USD $1.94 million) in a first financing...
Focus on Fab’entech
February 20th, 2015Fab’entech , innovative biopharmaceutical company member of Lyonbiopole is specialized since five years already , in the Treatment of Emerging Infectious...
Focus on ImmunID
January 23th, 2015ImmunID Announces Rapid Enrolment of Patients in its PREDICT-ID Melanoma Clinical Trial for Prediction of Response to an Immunotherapy...
Focus on Alizé Pharma
Décember 15th, 2014Alizé Pharma is a company member of Lyonbiopole, specialized in the development of biopharmaceuticals for the treatment of metabolic...
Focus on Theranexus
November 21th, 2014Theranexus is a biotechnology company spun off from CEA and member of Lyonbiopole. She has just completed a fundraising...
Focus on Erytech Pharma
October 29th, 2014Zoom sur Erytech Pharma
Focus on Genel
September 30th, 2014On July 3rd, 2014 , the start-up project Genel, hosted at the Grenoble business incubator GRAIN was created successfully....
Focus on Fluoptics
June 24th, 2014Fluoptics, Lyonbiopole member’s, based in Grenoble, develops and markets innovative solutions in the field of fluorescence image-guided surgery. Early...
Focus on Cellipse
May 28th, 2014Presentation Cellipse is a company member of Lyonbiopole based in Grenoble. It was created in early 2013 by three...